Patients with amyloid transthyretin (ATTR) amyloidosis represent a population that is likely to be particularly vulnerable to COVID-19 due to the multisystem nature of the disease (Fig. 1), and in many cases, the advanced age of the patients along with presensitization of their immune system due to the chronic inflammation that is a byproduct of abnormal amyloid deposits [17–23]. This evidence concerns the gene TTR and COVID-19.